Distinguished in HIV/AIDS

Dr. Marshall J. Glesby

Infectious Disease
Weill Medical College Of Cornell
525 E 68th St, 
New York, NY 
32 Years of Experience
Distinguished in HIV/AIDS
Weill Medical College Of Cornell
525 E 68th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marshall Glesby is an Infectious Disease provider in New York, New York. Dr. Glesby has been practicing medicine for over 32 years and is rated as a Distinguished provider by MediFind in the treatment of HIV/AIDS. His top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, and Leishmaniasis.

His clinical research consists of co-authoring 124 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 57 articles and participated in 3 clinical trials in the study of HIV/AIDS.

Specialties
Infectious Disease
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
PacificSource
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
525 E 68th St, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: Glecaprevir+Pibrentasvir, Ribavirin
Study Phase: Phase 2
Doxycycline for COPD in HIV-Infected Patients
Doxycycline for COPD in HIV-Infected Patients
Enrollment Status: Completed
Publish Date: July 21, 2022
Intervention Type: Drug
Study Phase: Not Applicable
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Enrollment Status: Completed
Publish Date: April 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: August 18, 2017
The Safety and Efficacy of Intravenous Anti-D for the Treatment of Thrombocytopenia in Patients With HCV Infection Prior to or During Treatment With Pegylated-interferon and Ribavirin
The Safety and Efficacy of Intravenous Anti-D for the Treatment of Thrombocytopenia in Patients With HCV Infection Prior to or During Treatment With Pegylated-interferon and Ribavirin
Enrollment Status: Terminated
Publish Date: May 16, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 11 Less Clinical Trials

124 Total Publications

Clinical Outcomes of Mpox Disease in Patients Treated with Tecovirimat.
Clinical Outcomes of Mpox Disease in Patients Treated with Tecovirimat.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 30, 2025
Similar Doctors
Elite in HIV/AIDS
Dr. Jihad S. Slim
Infectious Disease
Elite in HIV/AIDS
Dr. Jihad S. Slim
Infectious Disease

Njcri Physicians Group PC

393 Central Ave, 
Newark, NJ 
 (12.3 miles away)
973-483-3444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jihad Slim is an Infectious Disease provider in Newark, New Jersey. Dr. Slim is rated as a Distinguished provider by MediFind in the treatment of HIV/AIDS. His top areas of expertise are HIV/AIDS, Hepatitis C, COVID-19, Hepatitis, and Gastrostomy.

Wafaa M. El-Sadr
Elite in HIV/AIDS
Dr. Wafaa M. El-Sadr
Infectious Disease
Elite in HIV/AIDS
Dr. Wafaa M. El-Sadr
Infectious Disease
506 Malcolm X Blvd, Wp-522, 
New York, NY 
 (3.5 miles away)
212-939-2740
Languages Spoken:
English
See accepted insurances

Wafaa El-Sadr is an Infectious Disease provider in New York, New York. Dr. El-Sadr is rated as a Distinguished provider by MediFind in the treatment of HIV/AIDS. Her top areas of expertise are HIV/AIDS, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Ebola Virus Disease.

Judith A. Aberg
Elite in HIV/AIDS
Dr. Judith A. Aberg
Infectious Disease
Elite in HIV/AIDS
Dr. Judith A. Aberg
Infectious Disease

Icahn School Of Medicine At Mount Sinai

17 E 102nd St, 
New York, NY 
 (1.9 miles away)
212-659-8551
Languages Spoken:
English
See accepted insurances

Judith Aberg is an Infectious Disease provider in New York, New York. Dr. Aberg is rated as a Distinguished provider by MediFind in the treatment of HIV/AIDS. Her top areas of expertise are HIV/AIDS, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Vitamin D Deficiency.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Glesby's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile